Search

Your search keyword '"Ayres, Brandon D"' showing total 201 results
Start Over Author "Ayres, Brandon D"
201 results on '"Ayres, Brandon D"'

5. Improved Signs and Symptoms of Dry Eye Disease for Restasis® Patients Following a Single Tearcare® Treatment: Phase 2 of the SAHARA Study.

Author

Ayres, Brandon D, Bloomenstein, Marc R, Loh, Jennifer, Chester, Thomas, Saenz, Bobby, Echegoyen, Julio, Kannarr, Shane R, Rodriguez, Tomasita C, and Jr, Jaime E Dickerson

Subjects
*DRY eye syndromes, *EYE diseases, *SYMPTOMS, *THERMOTHERAPY, *EYE care
Abstract

aime E Dickerson Jr9,101Private Practice, Philadelphia, PA, USA; 2Schwartz Laser Eye Center, Scottsdale, AZ, USA; 3Loh Ophthalmology Associates, Miami, FL, USA; 4Cleveland Eye Clinic, Brecksville, OH, USA; 5Rosenberg School of Optometry, University of the Incarnate Word, San Antonio, TX, USA; 6LASIK San Antonio, Kerrville, TX, USA; 7Gordon Schanzlin New Vision Institute, La Jolla, CA, USA; 8Kannarr Eye Care, Pittsburg, KS, USA; 9Sight Sciences, Menlo Park, CA, USA; 10North Texas Eye Research Institute, University of North Texas Health Science Center, Fort Worth, TX, USA Correspondence: Jaime E Dickerson Jr, Email [email protected] Purpose: To evaluate dry eye disease (DED) signs and symptoms six months after a single treatment with Localized Heat Therapy (LHT) (TearCare, Sight Sciences) for patients previously treated for six months with cyclosporine (0.05%) ophthalmic emulsion (CsA) BID (Restasis, Allergan). Setting: Nineteen ophthalmic and optometric practices in 11 US states. Design: Multicenter, cross-over, six month extension to the SAHARA randomized, controlled trial (RCT). Included patients were those randomized to CsA in Phase 1 of the SAHARA RCT. Methods: This was the second phase of the SAHARA RCT in which, following the 6-month endpoint, all patients that had been randomized to CsA discontinued CsA and were treated with LHT and subsequently followed for an additional six months. Outcome measures at 12 months for CsA patients crossed over to LHT included TBUT, OSDI and MGSS. Results: One hundred and sixty-one patients (322 eyes) were analyzed. Mean (SD) baseline TBUT prior to CsA was 4.4 (1.2) seconds, 5.6 (2.6) at 6 months which improved to 6.6 (3.2) and 6.1 (2.8) seconds (both P < 0.001) at 9 and 12 months (3, 6 months post LHT). Mean (SD) OSDI was 50.0 (14.9) at baseline and 34.2 (21.5) after CsA. With LHT at 6 months, this improved to 30.0 (20.6) and 31.0 (19.5) at 9 and 12 months (P = 0.162 vs month 6, P < 0.0001 vs baseline). MGSS was 7.1 (3.2) at baseline, 13.3 (8.2) at the end of CsA treatment which improved to 17.4 (8.8) and 16.1 (9.0) at 9 and 12 months; both P < 0.001. Conclusion: SAHARA showed 6-month superiority of LHT to CsA in clinical signs and non-inferiority in symptom scores. This extension shows that patients treated with CsA for 6 months can achieve meaningful additional improvement in signs and symptoms lasting for as long as 6 months following a single LHT treatment without the need for topical prescription therapy. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

11. A Randomized, Controlled Trial Comparing Tearcare® and Cyclosporine Ophthalmic Emulsion for the Treatment of Dry Eye Disease (SAHARA).

Author

Ayres, Brandon D, Bloomenstein, Marc R, Loh, Jennifer, Chester, Thomas, Saenz, Bobby, Echegoyen, Julio, Kannarr, Shane R, Perez, Victor L, Rodriguez, Tomasita C, and Jr, Jaime E Dickerson

Subjects
*DRY eye syndromes, *MEIBOMIAN glands, *CYCLOSPORINE, *INTRAOCULAR pressure, *ACADEMIC medical centers, *OPTICAL goods stores, *LINSEED oil
Abstract

aime E Dickerson Jr10,111Private Practice, Philadelphia, PA, USA; 2Schwartz Laser Eye Center, Scottsdale, AZ, USA; 3Loh Ophthalmology Associates, Miami, FL, USA; 4Cleveland Eye Clinic, Brecksville, OH, USA; 5Rosenberg School of Optometry, University of the Incarnate Word, San Antonio, TX, USA; 6LASIK San Antonio, Kerrville, TX, USA; 7Gordon Schanzlin New Vision Institute, La Jolla, CA, USA; 8Kannarr Eye Care, Pittsburg, KS, USA; 9Department of Ophthalmology, Duke University Medical Center, Durham, NC, USA; 10Sight Sciences, Menlo Park, CA, USA; 11North Texas Eye Research Institute, University of North Texas Health Science Center, Fort Worth, TX, USACorrespondence: Jaime E Dickerson Jr, Email [email protected] Purpose: We compare outcomes in eyes with dry eye disease (DED) treated with TearCare (TC) or topical cyclosporine 0.05% (RESTASIS; CsA).Setting: Nineteen ophthalmic and optometric practices in 11 US states.Design: Multicenter, randomized, assessor-masked, controlled IRB-approved trial. Eligible subjects: ≥ 22 years of age, dry eye symptoms within 3– 6 months, Tear Break-up Time (TBUT) ≥ 1 to ≤ 7 s, Meibomian Gland Secretion Score (MGSS) ≤ 12, Ocular Surface Disease Index (OSDI) of 23– 79. Randomized (1:1) to TC or CsA. TC subjects treated at baseline and month 5; CsA was twice daily for 6 months.Methods: Follow-up visits were scheduled for Day 1, Week 1, Months 1, 3, and 6 with primary inference at Month 6. Primary outcomes: TBUT and OSDI; secondary outcomes: MGSS, conjunctival and corneal staining, eye dryness score (EDS), symptoms assessment in dry eye (SANDE) score, and Schirmer tear score (STS). Safety assessments included adverse events, best corrected visual acuity, intraocular pressure, and slit-lamp findings.Results: Overall, 345 subjects, 172 TC and 173 CsA. TBUT improved at all time points in both groups (p< 0.0001), with statistically greater improvement for TC versus CsA (p=0.0006). OSDI improved significantly at all time points in both groups (p< 0.0001) with no significant differences between treatments. MGSS and other measures of meibomian gland function improved significantly more with TC eyes versus CsA; other secondary outcomes showed significant improvements in both groups with no difference between groups. Treatment-related adverse events were uncommon (10 total, 8 in the CsA group consistent with prior CsA studies); most (9/10) mild.Conclusion: TC provides statistically superior and sustained improvement in TBUT and multiple measures of meibomian gland secretion, and non-inferior improvement in OSDI, corneal and conjunctival staining, SANDE, EDS, and STS versus CsA. TC should be a preferred treatment for DED associated with MGD. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

12. Delphi Panel Consensus Regarding Current Clinical Practice Management Options for Demodex blepharitis

Author

Farid, Marjan, primary, Ayres, Brandon D, additional, Donnenfeld, Eric, additional, Gaddie, Ian Benjamin, additional, Gupta, Preeya K, additional, Holland, Edward, additional, Lindstrom, Richard, additional, Pflugfelder, Stephen C, additional, Karpecki, Paul M, additional, Nichols, Kelly K, additional, Starr, Christopher E, additional, and Yeu, Elizabeth, additional

Published
2023
Full Text
View/download PDF

13. Corneal Outcomes Following Cataract Surgery Using Ophthalmic Viscosurgical Devices Composed of Chondroitin Sulfate-Hyaluronic Acid: A Systematic Review and Meta-Analysis

Author

Hsiao, Chia-Wen, Cheng, Hang, Ghafouri, Rana, Ferko, Nicole C., Ayres, Brandon D., Hsiao, Chia-Wen, Cheng, Hang, Ghafouri, Rana, Ferko, Nicole C., and Ayres, Brandon D.

Abstract

Background: Ophthalmic viscosurgical devices (OVDs) are commonly used during cataract surgery to protect the corneal endothelium. A systematic literature review and meta-analysis were conducted to assess the clinical evidence of OVDs composed of chondroitin sulfate-hyaluronic acid (CS-HA) versus other OVDs in maintaining endothelial cell density (ECD) and corneal thickness (CT). Methods: MEDLINE and EMBASE databases were searched from 2000 to 2020. Randomized controlled trials (RCTs, N ≥ 20 per group) comparing an OVD containing CS-HA (ie, VISCOAT®, DuoVisc® or DisCoVisc®) to any other OVD were included. The identified comparators were limited to the OVDs found in the literature, which included those composed of HA-only or hydroxypropyl methylcellulose (HPMC). Outcomes of focus included changes in ECD (baseline to 3 months) and CT (baseline to 24 hours). Meta-analyses were performed using R software, to assess mean differences (MD) in ECD and CT change between CS-HA OVDs and HA-only or HPMC OVDs. Results: A total of 966 abstracts were screened, and data were extracted from 12 RCTs. Meta-analyses using a random-effects model revealed significantly lower percent (%) decrease in ECD for CS-HA OVDs compared to both HA-only (MD: −4.10%; 95% CI: −5.81 to −2.40; p < 0.0001; 9 studies) and HPMC (MD: −6.47%; 95% CI: −10.41 to −2.52; p = 0.001; 2 studies) products. Similarly, % CT increase was significantly lower with CS-HA than with HA-only OVDs (MD: −3.22%; 95% CI: −6.24% to −0.20%; p = 0.04; 4 studies). However, there were no significant differences when comparing % CT change between CS-HA and HPMC OVDs (MD: 2.65%; 95% CI: −0.43% to 0.95%; p = 0.4; 2 studies). Conclusion: CS-HA OVDs lead to less postoperative loss of endothelial cells and may better protect corneal endothelium during cataract surgery, relative to other OVDs. Future randomized studies may be needed to solidify these findings.

Published
2023

14. Corneal Outcomes Following Cataract Surgery Using Ophthalmic Viscosurgical Devices Composed of Chondroitin Sulfate-Hyaluronic Acid: A Systematic Review and Meta-Analysis

Author

Hsiao,Chia-Wen, Cheng,Hang, Ghafouri,Rana, Ferko,Nicole C, Ayres,Brandon D, Hsiao,Chia-Wen, Cheng,Hang, Ghafouri,Rana, Ferko,Nicole C, and Ayres,Brandon D

Abstract

Chia-Wen Hsiao,1 Hang Cheng,1 Rana Ghafouri,2 Nicole C Ferko,2 Brandon D Ayres3 1Alcon, Fort Worth, TX, USA; 2Eversana, Burlington, ON, Canada; 3Thomas Jefferson University Hospital, Philadelphia, PA, USACorrespondence: Nicole C Ferko, Eversana Life Science Services, 3228 S Service Road, Burlington, ON, Canada, Tel +1 (905) 978-3111, Email nicole.ferko@eversana.comBackground: Ophthalmic viscosurgical devices (OVDs) are commonly used during cataract surgery to protect the corneal endothelium. A systematic literature review and meta-analysis were conducted to assess the clinical evidence of OVDs composed of chondroitin sulfate-hyaluronic acid (CS-HA) versus other OVDs in maintaining endothelial cell density (ECD) and corneal thickness (CT).Methods: MEDLINE and EMBASE databases were searched from 2000 to 2020. Randomized controlled trials (RCTs, N ≥ 20 per group) comparing an OVD containing CS-HA (ie, VISCOAT®, DuoVisc® or DisCoVisc®) to any other OVD were included. The identified comparators were limited to the OVDs found in the literature, which included those composed of HA-only or hydroxypropyl methylcellulose (HPMC). Outcomes of focus included changes in ECD (baseline to 3 months) and CT (baseline to 24 hours). Meta-analyses were performed using R software, to assess mean differences (MD) in ECD and CT change between CS-HA OVDs and HA-only or HPMC OVDs.Results: A total of 966 abstracts were screened, and data were extracted from 12 RCTs. Meta-analyses using a random-effects model revealed significantly lower percent (%) decrease in ECD for CS-HA OVDs compared to both HA-only (MD: − 4.10%; 95% CI: − 5.81 to − 2.40; p < 0.0001; 9 studies) and HPMC (MD: − 6.47%; 95% CI: − 10.41 to − 2.52; p = 0.001; 2 studies) products. Similarly, % CT increase was significantly lower with CS-HA than with HA-only OVDs (MD: − 3.22%; 95% CI: − 6.24% to − 0.20%; p = 0.04; 4 studies). However, there were no significant differences when comparing % CT change betw

Published
2023

15. Delphi Panel Consensus Regarding Current Clinical Practice Management Options for Demodex blepharitis

Author

Farid,Marjan, Ayres,Brandon D, Donnenfeld,Eric, Gaddie,Ian Benjamin, Gupta,Preeya K, Holland,Edward, Lindstrom,Richard, Pflugfelder,Stephen C, Karpecki,Paul M, Nichols,Kelly K, Starr,Christopher E, Yeu,Elizabeth, Farid,Marjan, Ayres,Brandon D, Donnenfeld,Eric, Gaddie,Ian Benjamin, Gupta,Preeya K, Holland,Edward, Lindstrom,Richard, Pflugfelder,Stephen C, Karpecki,Paul M, Nichols,Kelly K, Starr,Christopher E, and Yeu,Elizabeth

Abstract

Marjan Farid,1 Brandon D Ayres,2 Eric Donnenfeld,3 Ian Benjamin Gaddie,4 Preeya K Gupta,5 Edward Holland,6 Richard Lindstrom,7 Stephen C Pflugfelder,8 Paul M Karpecki,9 Kelly K Nichols,10 Christopher E Starr,11 Elizabeth Yeu12 1Gavin Herbert Eye Institute, UC-Irvine, Irvine, CA, USA; 2Wills Eye Hospital, Philadelphia, PA, USA; 3Ophthalmic Consultants of Long Island, Long Island, NY, USA; 4Gaddie Eye Centers, Louisville, KY, USA; 5Triangle Eye Consultants, Raleigh, NC and Tulane University, New Orleans, LA, USA; 6University of Cincinnati, Cincinnati, OH, USA; 7University of Minnesota, Minneapolis, MN, USA; 8Baylor College of Medicine, Houston, TX, USA; 9Kentucky Eye Institute, Lexington, KY, USA; 10University of Alabama at Birmingham, School of Optometry, Birmingham, AL, USA; 11Weill Cornell Medicine, New York, NY, USA; 12Virginia Eye Consultants, Norfolk, VA, USACorrespondence: Marjan Farid, University of California, 850 Health Sciences Road, Mail Code: 4375, Irvine, CA, 92697, USA, Tel +1 949 824-0327, Email mfarid@uci.eduPurpose: To obtain consensus on Demodex blepharitis (DB) treatment using a modified Delphi panel process.Methods: Literature search identified gaps in knowledge surrounding treatment of DB. Twelve ocular surface disease experts comprised the Demodex Expert Panel on Treatment and Eyelid Health (DEPTH). They completed a live roundtable discussion in addition to 3 surveys consisting of scaled, open-ended, true/false, and multiple-choice questions pertaining to the treatment of DB. Consensus for scaled questions using a 1 to 9 Likert scale was predefined as median scores of 7– 9 and 1– 3. For other question types, consensus was achieved when 8 of 12 panelists agreed.Results: The experts agreed that an effective therapeutic agent for treatment of DB would likely decrease the necessity of mechanical intervention, such as lid scrubs or blepharoexfoliation (Median = 8.5; Range 2– 9). When treating DB, panelists believed that collarettes serve as a s

Published
2023

18. Results of the United States Food and Drug Administration Clinical Trial of the CustomFlex Artificial Iris

Author

Ayres, Brandon D., primary, Fant, Barbara S., additional, Landis, Zachary C., additional, Miller, Kevin M., additional, Stulting, R. Doyle, additional, Cionni, Robert J., additional, Fram, Nicole R., additional, Hamilton, Stephen, additional, Hardten, David R., additional, Koch, Douglas D., additional, Masket, Samuel, additional, Price, Francis W., additional, Rosenthal, Kenneth J., additional, Hamill, M. Bowes, additional, and Snyder, Michael E., additional

Published
2022
Full Text
View/download PDF

19. Economic Impact Analysis of Custom Pak® on Cataract and Vitreoretinal Surgery in the United States

Author

Ayres, Brandon D., Gupta, Omesh P., Davis, Jonathan S., Hahn, Rebecca, Hsiao, Chia-Wen, Kara, Richard, Di Simplicio, Sandro, Ayres, Brandon D., Gupta, Omesh P., Davis, Jonathan S., Hahn, Rebecca, Hsiao, Chia-Wen, Kara, Richard, and Di Simplicio, Sandro

Abstract

PURPOSE: Implicit costs of surgical preparation and materials management for cataract/anterior segment and retinal/posterior segment procedures are often unquantified. Use of ophthalmological surgical procedure packs is common in these surgeries; however, there is little in the literature demonstrating their time and cost impacts. Understanding the costs and potential benefits of surgical pack procedure use is important for administrators in purchasing decision-making. The objective of this study is to estimate the economic impact of Alcon Custom Pak METHODS: We conducted a study in 2019 among US hospitals and ASCs using an online survey and a surgery timing exercise. Surgical technicians and supply chain managers were surveyed regarding current cataract and retina surgery practices including OR, materials management, and accounting tasks. Surgical technicians timed cataract and retina surgeries, recording activity timestamps and surgical supply use from Alcon Custom Pak and other sources. Using the survey and timing exercise inputs and literature and government sources, we developed a budget impact model (BIM) to quantify hidden costs of time and labor spent across the entire surgery supply life cycle. RESULTS: Representing a geographical mix of 99 facilities, surgical technicians (56 cataract/46 retina) and supply chain managers (23 cataract/24 retina) provided data for their institutions. Technicians timed 290 cataract and 250 retina surgeries. In the BIM, increasing baseline Custom Pak utilization to 100% of surgeries while also sourcing all relevant supplies from Custom Pak results in annual cost savings ranging from $92,273 to $217,675 across procedure type and setting, allowing for between 75 (retina ASC) and 266 (cataract hospital) potential additional procedures per facility/year. CONCLUSION: This study demonstrates that increasing Custom Pak usage can potentially save time, reduce hidden costs, and increase throughput.

Published
2022

20. Economic Impact Analysis of Custom Pak® on Cataract and Vitreoretinal Surgery in the United States

Author

Ayres,Brandon D, Gupta,Omesh P, Davis,Jonathan S, Hahn,Rebecca, Hsiao,Chia-Wen, Kara,Richard, Di Simplicio,Sandro, Ayres,Brandon D, Gupta,Omesh P, Davis,Jonathan S, Hahn,Rebecca, Hsiao,Chia-Wen, Kara,Richard, and Di Simplicio,Sandro

Abstract

Brandon D Ayres,1 Omesh P Gupta,2 Jonathan S Davis,3 Rebecca Hahn,3 Chia-Wen Hsiao,4 Richard Kara,4 Sandro Di Simplicio5 1Wills Eye Hospital, Philadelphia, PA, USA; 2The Retina Service of Wills Eye Institute, Thomas Jefferson University Hospital, Philadelphia, PA, USA; 3KJT Group, Inc., Rochester, NY, USA; 4Alcon Vision LLC, Fort Worth, TX, USA; 5Royal Victoria Infirmary, Newcastle Upon Tyne, UKCorrespondence: Jonathan S Davis, KJT Group, Inc, 777 Canal View Blvd, Rochester, NY, 14623, USA, Tel +1 585-269-4237, Email jonathansdavis@gmail.comPurpose: Implicit costs of surgical preparation and materials management for cataract/anterior segment and retinal/posterior segment procedures are often unquantified. Use of ophthalmological surgical procedure packs is common in these surgeries; however, there is little in the literature demonstrating their time and cost impacts. Understanding the costs and potential benefits of surgical pack procedure use is important for administrators in purchasing decision-making. The objective of this study is to estimate the economic impact of Alcon Custom Pak® on cataract and vitreoretinal (retina) surgery in hospitals and ambulatory surgical centers (ASCs) across operating room (OR), materials management, and accounting departments.Methods: We conducted a study in 2019 among US hospitals and ASCs using an online survey and a surgery timing exercise. Surgical technicians and supply chain managers were surveyed regarding current cataract and retina surgery practices including OR, materials management, and accounting tasks. Surgical technicians timed cataract and retina surgeries, recording activity timestamps and surgical supply use from Alcon Custom Pak and other sources. Using the survey and timing exercise inputs and literature and government sources, we developed a budget impact model (BIM) to quantify hidden costs of time and labor spent across the entire surgery supply life cycle.Results: Representing a geographical mix of 99 facili

Published
2022

21. Prior Contralateral Penetrating Keratoplasty Is a Risk Factor for Second Eye Graft Rejection.

Author

Shiuey, Eric J., Zhang, Qiang, Rapuano, Christopher J., Ayres, Brandon D., Hammersmith, Kristin M., Nagra, Parveen K., and Syed, Zeba A.

Subjects
GRAFT rejection, CORNEA surgery, PROPORTIONAL hazards models, KIDNEY failure, POLYPOIDAL choroidal vasculopathy
Abstract

To determine whether prior penetrating keratoplasty (PK) in the contralateral eye increases risk of second eye PK graft rejection. Cohort study of 593 consecutive PKs in transplant-naïve eyes (500 unilateral cases, 93 second eyes). Outcomes were compared between PKs performed in eyes with versus without a history of prior contralateral eye PK. Risks of rejection and failure were estimated using Cox proportional hazards models. Mean age was 53.7 ± 23.3 years; average follow-up was 4.00 ± 2.87 years. Rejection occurred in 211 (35.6%) grafts. The incidence of rejection was 34.0% in unilateral cases and 44.1% in second eyes with PK in the contralateral eye. Prior contralateral PK was a significant risk factor for graft rejection (HR = 1.42, 95% CI 1.01–2.01, p =.045) Contralateral PK is associated with increased risk of second eye graft rejection. Loss of ocular immune privilege is a possible mechanism. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

26. Clinical diagnosis and management of Demodexblepharitis: the DemodexExpert Panel on Treatment and Eyelid Health (DEPTH)

Author

Ayres, Brandon D., Donnenfeld, Eric, Farid, Marjan, Gaddie, Ian Benjamin, Gupta, Preeya K., Holland, Edward, Karpecki, Paul M., Lindstrom, Richard, Nichols, Kelly K., Pflugfelder, Stephen C., Starr, Christopher E., and Yeu, Elizabeth

Abstract

Background: Twelve ocular surface disease experts convened to achieve consensus about Demodexblepharitis (DB) using a modified Delphi panel process. Methods: Online surveys were administered using scaled, open-ended, true/false, and multiple-choice questions. Consensus for questions using a 1 to 9 Likert scale was predefined as median scores of 7–9 and 1–3. For other question types, consensus was achieved when 8 of 12 panellists agreed. Questions were randomized, and results of each survey informed the following survey. Results: Twelve practitioners comprised the DemodexExpert Panel on Treatment and Eyelid Health (DEPTH). Following 3 surveys, experts agreed that DB is chronic (n= 11) and recurrent (n= 12) and is often misdiagnosed. Consensus was achieved regarding inflammation driving symptoms (median = 7; range 7–9), collarettes as the most common sign (n= 10) and pathognomonic for DB (median = 9; range 8–9), and itching as the most common symptom (n= 12). Panellists agreed that DB may be diagnosed based on collarettes, mites, and/or patient symptoms (n= 10) and felt that patients unresponsive to typical therapies should be evaluated for DB (n= 12). Consensus about the most effective currently available OTC treatment was notreached. Conclusions: The Delphi methodology proved effective in establishing consensus about DB, including signs, symptoms, and diagnosis. Consensus was notreached about the best treatment or how to grade severity. With increased awareness, eyecare practitioners can offer DB patients better clinical outcomes. A follow-up Delphi panel is planned to obtain further consensus surrounding DB treatment.

Published
2023
Full Text
View/download PDF

27. A Randomized, Controlled Trial Comparing Tearcare® and Cyclosporine Ophthalmic Emulsion for the Treatment of Dry Eye Disease (SAHARA) [Response To Letter].

Author

Ayres, Brandon D, Bloomenstein, Marc R, Loh, Jennifer, Chester, Thomas, Saenz, Bobby, Echegoyen, Julio, Kannarr, Shane R, Perez, Victor L, Rodriguez, Tomasita C, and Jr, Jaime E Dickerson

Subjects
*DRY eye syndromes, *CYCLOSPORINE, *EYE care, *EMULSIONS, *RESEARCH institutes, *OPTICAL goods stores, *LINSEED oil
Abstract

aime E Dickerson Jr10,111Private Practice, Philadelphia, PA, USA; 2Schwartz Laser Eye Center, Scottsdale, AZ, USA; 3Loh Ophthalmology Associates, Miami, FL, USA; 4Cleveland Eye Clinic, Brecksville, OH, USA; 5Rosenberg School of Optometry, San Antonio, TX, USA; 6LASIK San Antonio, Kerrville, TX, USA; 7Gordon Schanzlin New Vision Institute, La Jolla, CA, USA; 8Kannarr Eye Care, Pittsburg, KS, USA; 9Bascom Palmer Eye Institute, University of Miami, Miami, FL, USA; 10Sight Sciences, Menlo Park, CA, USA; 11North Texas Eye Research Institute, University of North Texas Health Science Center, Fort Worth, TX, USA Correspondence: Jaime E Dickerson Jr, Email [email protected] View the original paper by Dr Ayres and colleagues This is in response to the Letter to the Editor [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

31. CONTRIBUTORS

Author

Abbott, Richard L., primary, Afshari, Natalie A., additional, Agrawal, Jaya, additional, Agrawal, Shishir, additional, Agrawal, Trilok P., additional, Akduman, Levent, additional, Akpek, Esen K., additional, Al-Sayyed, Amal, additional, Albini, Thomas A., additional, Alcorn, Deborah M., additional, Alwitry, Amar, additional, Amzel, Anouk, additional, Anderson, Nicole J., additional, Ansari, Ejaz A., additional, Antoszyk, Andrew, additional, Antoszyk, James H., additional, Aquavella, James V., additional, Arain, Sumaira A., additional, Arévalo, J. Fernando, additional, Arunagiri, Guruswami, additional, Arzabe, Carlos W., additional, Atchaneeyasakul, La-ongsri, additional, Atilla, Huban, additional, Aykan, Ümit, additional, Ayres, Brandon D., additional, Barbón, Juan J., additional, Bailey, Kristi, additional, Baloh, Frank G., additional, Barequet, Irina S., additional, Barkhuizen, André, additional, Bearn, Michael A., additional, Belfort, Rubens, additional, Bellows, A. Robert, additional, Berrocal, Audina M., additional, Bettink-Remeijer, Marijke Wefers, additional, Bhandari, Anuja, additional, Bhatti, M. Tariq, additional, Blumenkranz, Mark S., additional, Boboridis, Kostas G., additional, Bolling, James P., additional, Boniuk, Vivien, additional, Botelho, Paul Jorge, additional, Brazis, Paul W., additional, Bremner, Fion D., additional, Buckley, Edward G., additional, Bullock, John D., additional, Bushley, David Matthew, additional, Caldeira, Jorge Alberto F., additional, Carricajo, Anne, additional, Cavallini, Gian Maria, additional, Chan, Matilda Frances, additional, Chandler, Damon B., additional, Channa, H., additional, Char, Devron H., additional, Charles, Steve, additional, Chen, Teresa C., additional, Ching, Steven S.T., additional, Chiquet, Christophe, additional, Hyunchul, Phillip, additional, Chou, Timothy Y., additional, Christiansen, Stephen P., additional, Chung, Kelly D., additional, Cioffi, George A., additional, Clarke, Michael P., additional, Coats, David K., additional, Cohen, Elisabeth J., additional, Conway, R. Max, additional, Creuzot-Garcher, Catherine, additional, Cunningham, Emmett T., additional, Curtis, Theodore H., additional, Dailey, Roger A., additional, Davis, Richard M., additional, Cock, Romain De, additional, de Faber, Jan-Tjeerd H.N., additional, de la Mano, Daniel, additional, Dekkers, Nick W.H.M., additional, Monte, Monte Anthony Del, additional, Rocca, David A. Della, additional, Rocca, Robert C. Della, additional, Dhaliwal, Deepinder K., additional, Do, Diana V., additional, Dolman, Peter J., additional, Donahue, Sean P., additional, Donnenfeld, Eric D., additional, Duguid, Graham, additional, Duker, Jay S., additional, Dunn, James P., additional, Dunn, Steven P., additional, Duong, Hon-Vu Q., additional, Egan, Robert A., additional, Eichler, Michael D., additional, El-Dairi, Mays, additional, Ellis, Forrest J., additional, Emerson, Geoffrey, additional, Emerson, M. Vaughn, additional, Enyedi, Laura B., additional, Evans, Teodoro, additional, Falardeau, Julie, additional, Faris, Bishara M., additional, Feitl, Marianne E., additional, Felton, Warren L., additional, Feman, Stephen S., additional, ffytche, Timothy J, additional, Flaxel, Christina J., additional, Foroozan, Rod, additional, Foster, Allen, additional, Fraunfelder, Frederick T., additional, Fraunfelder, Frederick W., additional, Freeman, H. Mackenzie, additional, Friedlaender, Mitchell H., additional, Frohman, Larry P., additional, Fung, Wayne E., additional, Gain, Philippe, additional, Gaitan, Jaime R., additional, Gancher, Stephen, additional, Gard, Tim, additional, Gattey, Devin M., additional, Gehlbach, Peter L., additional, Ghajarnia, Mehdi, additional, Ghanem, Vinícius Coral, additional, Ghosh, Amit Kumar, additional, Ghosh, Chandak, additional, Giegengack, Matthew, additional, Gladstone, Geoffrey, additional, Gold, Daniel H., additional, Golub, Richard L., additional, Gombos, Dan S., additional, Gombos, George M., additional, Good, William V., additional, Goodman, Shawn, additional, Gottsch, John D., additional, Goverdhan, Srinivas, additional, Grimson, Baird S., additional, Güemes, Adolfo, additional, Guerra, Roberto, additional, Haller, Julia A., additional, Hammersmith, Kristin M., additional, Handelman, Irvin L., additional, Hargrove, Roderick N., additional, Harney, Michael S., additional, Harper, Richard A., additional, Hatt, Sarah R., additional, Hawkins, Barbara S., additional, Hayreh, Sohan S., additional, Heiligenhaus, Arnd, additional, Heinz, Carsten, additional, Herndon, Leon W., additional, Hickman, Simon J., additional, Hirano, Koji, additional, Holland, Edward J., additional, Holland, Gary N., additional, Holz, Eric R., additional, Hommura, Sachiko, additional, Horn, Jeffrey D., additional, Hornick, Richard B., additional, Hoskins, H. Dunbar, additional, Hung, James W., additional, Hunter, Brian A., additional, Hunter, Krista A., additional, Hunyor, Alex P., additional, Hurwitz, Brian, additional, Hwang, Thomas S., additional, Hyndiuk, Robert A., additional, Ilhan-Sarac, Ozge, additional, Ing, Edsel, additional, Ino-ue, Masanori, additional, Isada, Carlos M., additional, Iturriaga, Saylin, additional, Iuorno, Joseph D., additional, Iwach, Andrew G., additional, Iyer, Mohan N., additional, Izquierdo, Natalio J., additional, Jampol, Lee M., additional, Johnston, Suzanne, additional, Kadayifçilar, Sibel, additional, Kaden, Ian H., additional, Kaimbo, Dieudonne Kaimbo Wa, additional, Kapur, Rashmis, additional, Kastl, Peter R., additional, Katsavounidou, Garyfallia, additional, Kazerouni, Ayat, additional, Kazim, Michael, additional, Kedhar, Sanjay R., additional, Keech, Ronald V., additional, Kersten, Robert C., additional, Keys, Marshall P., additional, Khanna, Sangeeta, additional, Khaw, Peng Tee, additional, Kinyoun, James L., additional, Kirwan, Caitriona, additional, Kivelä, Tero, additional, Klein, Michael L., additional, Klotz, Stephen A., additional, Ko, John, additional, Kowalski, Regis P., additional, Krachmer, Jay H., additional, Krupin, Theodore, additional, Kuhn, Ferenc, additional, Kulkarni, Abhaya Vivek, additional, Kwun, Robert C., additional, Laibson, Peter R., additional, Lakhanpal, Rohit R., additional, Lam, Byron L., additional, Lamer, Laurent, additional, Lawlor, David P., additional, Lawton, Andrew W., additional, Leahey, Alan B., additional, LeBoyer, Russell, additional, Lee, Andrew G., additional, Lee, Wen-Hsiang, additional, Lee, William Barry, additional, Lehman, Sharon S., additional, Leibowitz, Howard M., additional, Leong, James, additional, Levin, Alex V., additional, Levin, Leonard A., additional, Levine, Mark R., additional, Levy, Norman S., additional, Liesegang, Thomas J., additional, Lim, Lyndell L., additional, Lin, Linda H., additional, Lisman, Richard D., additional, Litoff, David, additional, Liu, James C., additional, Loft, Evan, additional, Lubritz, Ronald R., additional, Mabey, David C.W., additional, Mackie, Ian A., additional, Maguluri, Srilakshmi, additional, Maliki, M., additional, Mamalis, Nick, additional, Mannis, Mark J., additional, Mansberger, Steven L., additional, Mansour, Ahmad M., additional, Marcon, Alexandre S., additional, Marcon, Italo M., additional, Marsh, Peter B., additional, Mather, Rookaya, additional, Mathers, William D., additional, Saari, K. Matti, additional, Mawn, Louise A., additional, McAllum, Penny J., additional, McCallum, Rex M., additional, McCluskey, Peter, additional, McCormick, Gregory J., additional, McCormick, Steven A., additional, McCulley, James P., additional, McHenry, John G., additional, McNab, Alan A., additional, Mee, Jared J., additional, Meier, Douglas L., additional, Meisler, David M., additional, Merin, Saul C., additional, Meyer, Dale R., additional, Meyer, Roger F., additional, Michels, Kevin S., additional, Milman, Tatyana, additional, Mintz, Roni, additional, Morel, Chantal F, additional, Morris, William R., additional, Moster, Mark L., additional, Mourani, John, additional, Muccioli, Cristina, additional, Mudumbai, Raghu C., additional, Murillo-Lopez, Fernando H., additional, Myint, Shoib, additional, Nagra, Parveen K, additional, Naoumi, A, additional, Nassif, John, additional, Nee, Michelle T., additional, Netto, Marcelo V., additional, Ng, John D., additional, Nguyen, Hau T., additional, Nguyen, Quan Dong, additional, O'Day, Denis M., additional, O'Day, A. Justin, additional, O'Halloran, Henry S., additional, O'Keefe, Michael, additional, Okamoto, Fumiki, additional, Olson, Richard J., additional, Orcutt, James C., additional, Dundar, Sema Oruc, additional, Osbourne, Aaron, additional, Palazzi, Maristela Amaral, additional, Palmer, Earl A., additional, Papadopoulos, Maria, additional, Parnell, Jeffrey R., additional, Parsa, Cameron F., additional, Patel, Sanjay V., additional, Patterson, Emily, additional, Pendergast, Scott D., additional, Perry, Henry D., additional, Peters, Keith Roberson, additional, Po, Stephanie M., additional, Pokroy, Russell, additional, Putterman, Allen Michael, additional, Queiro, Rubén, additional, Rafiei, Nastaran, additional, Rahmani, Bahram, additional, Rapuano, Christopher J, additional, Rasheed, Karim, additional, Rathinam, S.R., additional, Raymond, Lawrence A., additional, Read, Russell W., additional, Lafayette, August, additional, Recchia, Franco M., additional, Reidy, James J., additional, Reynolds, Adam C., additional, Rich, Larry F., additional, Ritch, Robert, additional, Robb, Richard M., additional, Robert, Pierre-Yves, additional, Robertson, Joseph E., additional, Roh, Shiyoung, additional, Romanet, Jean-Paul, additional, Rootman, Jack, additional, Roque, Barbara L., additional, Roque, Manolette R., additional, Rosenbaum, Arthur L., additional, Rosenbaum, James Todd, additional, Roy, F. Hampton, additional, Rundle, Paul A., additional, Sadun, Alfredo A., additional, Saffra, Norman A., additional, Salim, Sarwat, additional, Samples, John R., additional, Santiago, Alvina Pauline D, additional, Saperstein, David A., additional, Saunders, Richard A., additional, Savage, James A., additional, Scheufele, Tina A., additional, Schiedler, Vivian, additional, Schlesinger, Thomas K., additional, Schlossman, Abraham, additional, Schwartz, Lee K., additional, Scott, Ingrid U., additional, Scruggs, Jennifer, additional, Segal, Ernesto I., additional, Shalaby, Ismail A., additional, Sheikh, Aziz, additional, Sheppard, John D., additional, Sherman, Mark D., additional, Shields, Carol L., additional, Shields, Jerry A., additional, Singh, Amarpreet, additional, Singh, Christopher N., additional, Singman, Eric L., additional, Siracuse-Lee, Donna, additional, Smalley, Aaron D., additional, Smith, Patricia W., additional, Solomon, Anthony W., additional, Souhail, Hassane, additional, Spitzberg, Daniel H., additional, Spoor, Thomas C., additional, Stamper, Robert L., additional, Stark, Walter J., additional, Steele, Eric A., additional, Steinemann, Thomas L., additional, Stout, Ann U., additional, Stout, J. Timothy, additional, Stulting, R. Doyle, additional, Sugar, Alan, additional, Sugar, Joel, additional, Suh, Donny W., additional, Suhler, Eric B., additional, Sullivan, John H., additional, Sutphin, John Everett, additional, Swan, Kenneth C., additional, Tabbara, Khalid F., additional, Tamber, Mandeep S., additional, Tanna, Angelo P., additional, Tatlipinar, Sinan, additional, Tayani, Ramin, additional, Teichmann, Klaus D., additional, Terry, Mark A., additional, Tham, Clement Chee Yung, additional, Therzaz, A., additional, Thuret, Gilles, additional, Tinley, Christopher Graham, additional, Tongue, Andrea C., additional, Torres, Rodrigo J., additional, Tower, Robert N., additional, Traboulsi, Elias I, additional, Trikha, Rupan, additional, Tripathi, Brenda J., additional, Tripathi, Ramesh C., additional, Tugal-Tutkun, Ilknur, additional, Tung, Irene, additional, Evendingen, Judith A. M. Van, additional, Vaudaux, Jean D., additional, Wairagkar, Niteen S, additional, Walrath, Joseph D., additional, Walsh, Rory McConn, additional, Walton, David S., additional, Warwar, Ronald E., additional, Watson, Peter G., additional, Weiter, John J., additional, Weleber, Richard G., additional, Wertz, Fleming D., additional, Westra, Igor, additional, Wheeler, David T., additional, Wilkinson, Charles P., additional, Wilson, David J., additional, Wilson, M. Edward, additional, Wilson, Matthew W., additional, Wilson, Steven E, additional, Wobig, John L., additional, Wood, Terry D., additional, Wu, Lihteh, additional, Yalcinbayir, Ozgur, additional, Ying, Howard Shann-Cherng, additional, Youssef, Peter N., additional, and Zaidman, Gerald W., additional

Published
2008
Full Text
View/download PDF

33. Contributors

Author

Ayres, Brandon D., primary, Azuara‐Blanco, Augusto, additional, Bailey, Robert S., additional, Baldassano, Vincent F., additional, Baumal, Caroline R., additional, Bedrossian, Edward H., additional, Bilyk, Jurij R., additional, Blice, Jeffrey P., additional, Borne, Michael J., additional, Brooks, Steven E., additional, Buerger, David G., additional, Cohen, Elisabeth J., additional, Cohen, Marc S., additional, Jude Cox, Mary, additional, De Potter, Patric, additional, Desai, Vinay N., additional, Dugan, John D., additional, Duker, Jay S., additional, Eagle, Ralph C., additional, Fineman, Mitchell S., additional, Gault, Janice A., additional, Gausas, Roberta E., additional, Gum, Kenneth B., additional, Hannush, Sadeer B., additional, Henderer, Jeffrey D., additional, Hykin, Philip G., additional, Khatana, Anup, additional, Kim, Terry, additional, Lee, Stephen Y., additional, Maguire, Joseph I., additional, McNamara, J. Arch, additional, Moster, Marlene R., additional, Nelson, Leonard B., additional, Olitsky, Scott E., additional, Penne, Robert B., additional, Perry, Julian D., additional, Raber, Irving, additional, Rapuano, Christopher J., additional, Reeves, Sherman W., additional, Reinecke, Robert D., additional, Repke, Carolyn S., additional, Rhee, Douglas J., additional, Riveroll, Lorena, additional, Savino, Peter J., additional, Schanzer, Barry, additional, Schnall, Bruce M., additional, Shields, Carol L., additional, Shields, Jerry A., additional, Sivaprasad, Sobha, additional, Swartz, Nancy G., additional, Spaeth, George L., additional, Tabas, Janine G., additional, Tamhankar, Madhura, additional, Tasman, William, additional, Tipperman, Richard, additional, Tyson, Sydney, additional, Vander, James F., additional, Vrabec, Tamara R., additional, Wilson, Richard P., additional, and Wong, Vernon K.W., additional

Published
2007
Full Text
View/download PDF

35. Reply to: Endophthalmitis Rates and Clinical Outcomes Following Penetrating and Endothelial Keratoplasty

Author

Borkar, Durga S., primary, Wibbelsman, Turner D., additional, Buch, Preema M., additional, Rapuano, Sara B., additional, Obeid, Anthony, additional, Ho, Allen C., additional, Hsu, Jason, additional, Regillo, Carl D., additional, Ayres, Brandon D., additional, Hammersmith, Kristin M., additional, Nagra, Parveen K., additional, Raber, Irving M., additional, Rapuano, Christopher J., additional, and Syed, Zeba A., additional

Published
2019
Full Text
View/download PDF

37. Endophthalmitis Rates and Clinical Outcomes Following Penetrating and Endothelial Keratoplasty

Author

Borkar, Durga S., primary, Wibbelsman, Turner D., additional, Buch, Preema M., additional, Rapuano, Sara B., additional, Obeid, Anthony, additional, Ho, Allen C., additional, Hsu, Jason, additional, Regillo, Carl D., additional, Ayres, Brandon D., additional, Hammersmith, Kristin M., additional, Nagra, Parveen K., additional, Raber, Irving M., additional, Rapuano, Christopher J., additional, and Syed, Zeba A., additional

Published
2019
Full Text
View/download PDF

40. Phototherapeutic Keratectomy With Intraoperative Mitomycin C to Prevent Recurrent Anterior Corneal Pathology

Author

Ayres, Brandon D., Hammersmith, Kristin M., Laibson, Peter R., and Rapuano, Christopher J.

Subjects
Mitomycin, Health
Abstract

To link to full-text access for this article, visit this link: http://dx.doi.org/10.1016/j.ajo.2006.03.041 Byline: Brandon D. Ayres, Kristin M. Hammersmith, Peter R. Laibson, Christopher J. Rapuano Abstract: To determine the safety and efficacy of the use of intraoperative mitomycin C (MMC) during phototherapeutic keratectomy (PTK) for anterior corneal disease. Author Affiliation: Cornea Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania. Article History: Accepted 16 March 2006 Article Note: (footnote) Supported by the Corneal Fellowship Fund, Philadelphia, Pennsylvania.

Published
2006

44. FOCAL POINTS®: Management of the Aphakic Patient.

Author

Ayres, Brandon D., Shulman, Matthew D., and Meeker, Austin R.

Subjects
*CORNEAL transplantation, *VITRECTOMY, *SURGICAL site, *TRAUMA surgery, *CATARACT surgery, *SUTURING, *HYPODERMIC needles
Published
2019

46. Sjogren's syndrome screening and dry eye: new test aims to diagnose early, may have major impact

Author

Ayres, Brandon D.

Subjects
Dry eye syndromes -- Diagnosis -- Causes of -- Research -- Reports, Sjogren's syndrome -- Diagnosis -- Research -- Reports, Health
Abstract

IN THE PAST, Sjogren's syndrome has been challenging to diagnose, with limited tools and invasive procedures. Traditional biomarkers associated with detecting Sjogren's syndrome are less likely to detect the disease [...]

Published
2014

49. Contributors

Author

Abugo, Usiwoma, Ayres, Brandon D., Azari, Amir A., Azuara-Blanco, Augusto, Bailey, Robert S., Jr., Baldassano, Vincent F., Jr., Baumal, Caroline R., Bedrossian, Edward H., Jr., Bilyk, Jurij R., Blice, Jeffrey P., Borne, Michael J., Brooks, Steven E., Buerger, David G., Cohen, Elizabeth J., Cohen, Marc S., Cox, Mary J., DiDomenico, Kristin, Droms, Rebecca, Dugan, John D., Jr., Duker, Jay S., Eagle, Ralph C., Jr., Fineman, Mitchell S., Gault, Janice A., Gausas, Roberta E., Gum, Kenneth B., Gupta, Shipra, Hannush, Sadeer B., Harasymowycz, Paul, Henderer, Jeffrey D., Hykin, Philip G., Kim, Terry, Kim, Grace L., Koutsiouki, Chrysoula, Langelier, Nicole A., Lesniak, Sebastian P., Maguire, Joseph I., II, Moster, Mark L., Moster, Marlene R., Mukherjee, Nisha, Nelson, Leonard B., Olitsky, Scott E., Penne, Robert B., Perry, Julian D., Raber, Irving, Rahimy, Ehsan, J. Rapuano, Christopher, Reeves, Sherman W., Repke, Carolyn S., J. Rhee, Douglas, Riveroll-Hannush, Lorena, Rubinstein, Tal J., Salvin, Jonathan H., Savino, Peter J., Schanzer, Barry, Schnall, Bruce M., Shields, Carol L., Shields, Jerry A., Sivaprasad, Sobha, Spaeth, George L., Swartz, Nancy G., Tabas, Janine G., Tasman, William, Theventhiran, Alexander B., Tibbits, Michael D., Tipperman, Richard, Tyson, Sydney, Vander, James F., Vrabec, Tamara R., Wang, Jing, Wilson, Richard P., and Yeager, Lauren B.

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results